Video - Results from #50

Advanced Kidney Cancer VL

Evolution of the NCCN Guidelines for Kidney Cancer -Tian Zhang Details (Length of Discussion: 12 min) Tian Zhang and Charles Ryan highlight recent updates in the NCCN treatment guidelines for kidney cancer resulting from data leading to changes in treatment options. Incorporation of initial diagnosis, disease biology, risk category, and clinical factors assist with selecting the most appropriate therapy for these patients. Biographies: Tian Zhang, MD, Assistant Profe...
Systemic Therapy Options for Renal Cell Carcinoma - Monty Pal Details Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space. Monty explains the clinical applications, considering appropriate patient selection and toxicity profile relevant in decision making. Biographies: Sumanta (Monty) Kumar Pal, MD Charles J. Ryan, MD Related Content: Cabozantinib Versus Sunitinib As Initial Targeted Therapy f...
The Use of Molecular Profile in Renal Cancer - Martin Voss Details (Length of Discussion: 10 min) Daniel George and Martin Voss discuss the evolving management of patients with advanced renal cell carcinoma with a focus on the genomic landscape in high risk localized disease. Based on molecular profiles, we may be able to prognosticate more accurately on their risk for recurrence. Applicability of this biomarker data will guide the future in appropriate therapeut...
ASSET, A Pilot Study Using Exercise Physiology in Advanced Renal Cell Carcinoma - Mike Harrison Details Michael Harrison and Alicia Morgans discuss the ASSET trial, a pilot study looking at the drug sunitinib, and its impact on cardiopulmonary function in patients with metastatic kidney cancer. Harrison reviews in detail, the rationale for the study and why the phenomenology of fatigue using exercise physiology may be useful information for clinicians in the future. Biographies: Michael Harrison, MD...
A Review of Adjuvant Studies in Advanced Renal Cell Carcinoma - Tian Zhang Details (Length of Discussion: 18 min) Tian Zhang and Alicia Morgans provide an overview of the trials that are ongoing in the advanced renal cell space. They cover a spectrum from neoadjuvant, to adjuvant, with in-depth highlights on Keynote 564. The relevance in balancing therapy choices with that of toxicities is an important part of the treatment plan for patients as well as a strong consideration in...
CABOSUN Trial Plus an In-depth Discussion of Kidney Cancer Treatments - Toni Choueiri Details (Length of Discussion: 22 min) Alicia Morgans and Toni Choueiri engage in a discussion on the treatment options available for mRCC. Toni presents a thorough review of the CABOSUN results, further addressing the process of choosing the right first-line therapy for these patients with intermediate, and poor risk disease. His extensive work in research provides an optimistic vision of having a biomar...
CARMENA: Practice Changing Strategies for Kidney Cancer Details (Length of Discussion: 6 min) Charles Ryan and Dan George reflect on the dramatic changes clinicians have seen over the last 12 years in treating kidney cancer. Dan reviews the highlights of the CARMENA trial and the impact that the results have made to treatment strategies for patients, stressing the value of collaborative care and patient selection. Biographies: Daniel George, MD Charles J. Ryan...